Liver Cancer, Pain Management
Conditions
Keywords
Epidural Analgesia, Intravenous Patient Controlled, 15-148
Brief summary
The purpose of this study is to learn whether patient-controlled epidural analgesia (PCEA) is a better method for managing pain after liver resection compared to patient-controlled analgesia (IV PCA). Currently, the standard pain control method for liver resection patients is IV PCA. There is not enough data on how epidural (PCEA) relieves pain and movement on a day to day basis after liver resection.
Interventions
OTHERIV PCA
Patients undergoing IV PCA for pain control will have intravenous (IV) analgesia provided through a demand pump started in the recovery room.
OTHERPCEA
Patients in this group will have the epidural catheter placed by the anesthesia pain service team in the pre-surgical center (PSC) as performed routinely at MSKCC. The epidural will be used intra-operatively at the end of liver resection phase of the surgical procedure, once the specimen has been extracted, and continued subsequently in the post-operative phase for pain management.
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults (age 18 years or older) who are able to provide informed consent. * Patients undergoing open elective liver resection for primary liver pathology (benign or malignant) or secondary metastatic liver disease, including patients undergoing concomitant surgical procedures (such as colorectal resection or debulking procedures), with no contraindication to the insertion of an epidural catheter (localized infection, septicemia, or pre-operative coagulopathy).
Exclusion criteria
* Patients with a history of documented anaphylaxis or contraindication to any of the study medications or standardized intra-operative medications. These include dilaudid, fentanyl, and bupivacaine. * Patients with pain at rest or with movement measured by NRS \>2. * Patients receiving high dose opioids on a chronic basis (greater than or equivalent to 60mg of morphine per day). * Patients with severe chronic obstructive pulmonary disease (COPD) defined as an FEV1 \<50%. * Patients with significant cognitive impairment or documented psychologic impairment. * Contraindication to epidural catheter placement including bleeding diathesis (essential thrombocythemia, idiopathic thrombocytopenic purpura, von Willebrand disease, and hemophilia A or B), neurological dysfunction (multiple sclerosis, subacute myelo-opticoneuropathy or preexisting lower limb neurological deficit), prior extensive spinal surgery or major spinal deformity, pre-operative use of anti-coagulant with planned use of therapeutic dose of anti-coagulant in post-operatively, documented pre-operative coagulopathy (INR greater than 1.3 not on Coumadin or PTT greater than 42), platelets less than 100,000/μL, or evidence of infection at potential epidural site. * Cirrhotic patients. When incidentally discovered intra-operatively, patients will be excluded from the study and replaced, but will be followed for primary and secondary endpoints. * Patients with poor performance status preoperatively such that they are unable to walk up two flights of stairs. * Patients taking any opioid agonist/antagonist medication (i.e. Buprenorphine)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ability to detect a 2-point NRS scale difference | 1 year | The primary endpoint assesses differences in pain control between PCEA and IV PCA after a get up and go test performed on POD2 during pain rounds, evaluated using a NRS pain score. |
Countries
United States
Outcome results
None listed